Autopsy report · NCT01408043
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Cause of deathSlow enrollment
“Slow Accrual”
Life of this trial
- Registered 2 months before it started.
- Ran for about 4 years 7 months before it stopped.
- 25 participants enrolled.
- Results were posted on the registry 3 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Case Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission; Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma
- Interventions
- plerixafor; filgrastim; etoposide; leukapheresis
- Participants
- 25
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.